Phase Ib/IIa randomized study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB
Authors:
- 5 July 2024
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 81 (6) , 949-959
Abstract
No abstract availableKeywords
Funding Information
- National Institute for Health and Care Research
This publication has 44 references indexed in Scilit:
- Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot studyJournal of Hepatology, 2019
- Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)eClinicalMedicine, 2019
- Serum Hepatitis B Virus RNA as a Potential Diagnostic Biomarker During Chronic Hepatitis B Virus InfectionClinical Liver Disease, 2019
- Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapyCancer Treatment Reviews, 2019
- Taiwan consensus statement on the management of chronic hepatitis BJournal of the Formosan Medical Association, 2019
- Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy AdultsEBioMedicine, 2018
- The role of quantitative hepatitis B surface antigen revisitedJournal of Hepatology, 2017
- Therapeutic vaccines in HBV: lessons from HCVMedical Microbiology and Immunology, 2015
- Reduction of Hepatitis B Surface Antigen Levels And Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients Receiving 10 Years of Nucleoside Analogue TherapyHepatology, 2013
- Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis BInflammation Research, 2010